Systemic antifungal treatment after posaconazole prophylaxis: results from the SEIFEM 2010-C survey.
暂无分享,去创建一个
L. Pagano | F. Aversa | G. Nadali | M. Caira | A. Nosari | M. Picardi | A. Busca | B. Martino | P. Salutari | M. Tumbarello | C. Cattaneo | C. Castagnola | A. Candoni | R. Fanci | S. Ballanti | L. Verga | F. Lessi | M. E. Mitra
[1] L. Pagano,et al. The role of primary antifungal prophylaxis in patients with haematological malignancies. , 2014, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[2] T. C. White,et al. Pharmacokinetics of posaconazole within epithelial cells and fungi: insights into potential mechanisms of action during treatment and prophylaxis. , 2013, The Journal of infectious diseases.
[3] L. Pagano,et al. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients , 2013, Hematological oncology.
[4] L. Pagano,et al. Hema e-Chart registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections. , 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[5] John W. Wilson,et al. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole , 2013, American journal of hematology.
[6] J. Serrano,et al. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin B is not negatively affected by prior administration of mold-active azoles. , 2013, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
[7] L. Pagano,et al. Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] R. Rajendran,et al. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis , 2011, Journal of Clinical Pathology.
[9] P. Vanhems,et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. , 2011, Medical mycology.
[10] L. Pagano,et al. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project , 2011, Haematologica.
[11] K. Sepkowitz,et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] G. Egerer,et al. Posaconazole prophylaxis in patients with acute myelogenous leukaemia – results from an observational study , 2011, Mycoses.
[13] M. Shivaprakash,et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study , 2010, Bone Marrow Transplantation.
[14] M. Hallek,et al. Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. , 2010, The Journal of antimicrobial chemotherapy.
[15] M. Shivaprakash,et al. An EORTC Phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. , 2009, The Journal of antimicrobial chemotherapy.
[16] Patricia Muñoz,et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] J. Wingard,et al. Changes in causes of death over time after treatment for invasive aspergillosis , 2008, Cancer.
[18] L. Pagano,et al. Invasive Aspergillosis in patients with acute leukemia: update on morbidity and mortality--SEIFEM-C Report. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[19] J. Perfect,et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. , 2007, The New England journal of medicine.
[20] J. Lipton,et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. , 2007, The New England journal of medicine.
[21] Thomas J Walsh,et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. , 2004, The New England journal of medicine.